Gregory A Masters
Overview
Explore the profile of Gregory A Masters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farris M, Mix M, Wang X, Jaszewski B, Foster N, Masters G, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2440673.
PMID: 39446327
Importance: The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors...
2.
Weidhaas J, Hu C, Komaki R, Masters G, Blumenschein G, Chang J, et al.
Cancer Res Commun
. 2023 Sep;
3(10):2074-2081.
PMID: 37728512
Purpose: RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non-small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy,...
3.
Bulen B, Khazanov N, Hovelson D, Lamb L, Matrana M, Burkard M, et al.
Cancer Res Commun
. 2023 Jul;
3(7):1335-1349.
PMID: 37497337
Significance: This study confirms the utility of the integrative IRS biomarker for predicting anti-PD-L1/PD-1 benefit. IRS significantly improved upon currently available biomarkers, including PD-L1 IHC, TMB, and MSI status. Additional...
4.
Ligibel J, Pierce L, Bender C, Crane T, Dieli-Conwright C, Hopkins J, et al.
Cancer
. 2022 Apr;
128(14):2817-2825.
PMID: 35442532
Background: The American Society of Clinical Oncology (ASCO) surveyed cancer patients to assess practice patterns related to weight, diet, and exercise as a part of cancer care. Methods: An online...
5.
Brahmer J, Abu-Sbeih H, Ascierto P, Brufsky J, Cappelli L, Cortazar F, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34172516
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks...
6.
Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar L, et al.
Lung Cancer
. 2021 Apr;
156():68-71.
PMID: 33894496
Introduction: The CALGB 30610/RTOG 0538 randomized trial was designed to test whether high-dose thoracic radiotherapy (TRT) would improve survival compared with 45 Gy twice-daily (BID) TRT in limited stage small...
7.
Bradley J, Hu C, Komaki R, Masters G, Blumenschein G, Schild S, et al.
J Clin Oncol
. 2019 Dec;
38(7):706-714.
PMID: 31841363
Purpose: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC)....
8.
Shah D, Masters G
Surg Oncol Clin N Am
. 2019 Nov;
29(1):15-21.
PMID: 31757310
Lung cancer remains second most common cancer in men and women in the United States. More than 50% of patients are diagnosed in the advanced stage. Traditionally, chemotherapy has been...
9.
Rashid A, Venigalla S, Dzeda M, Masters G
Cureus
. 2019 May;
11(3):e4264.
PMID: 31139523
As immunotherapy continues to translate to the clinic and is combined with existing modalities, such as radiation therapy, novel treatment response patterns have been observed which complicate conventional clinical assessment...
10.
Laslett N, Park S, Masters G, Biggs D, Schneider C, Misleh J, et al.
Cancer Med
. 2018 Jun;
7(7):2969-2973.
PMID: 29905018
Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a...